Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective conscientiously but unsuccessfully to produce an one-time therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be used is actually an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV happen to be closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of my last several shares. My first CytoDyn post, “CytoDyn: What To Do When It is Too Good In order to Be True?”, set away all of the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such a highly promotional image in the Uptick Newswire interview that I came away with a poor impression of the business.

Irony of irony, my bad impression of the company has grown steadily, however, the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger at the moment still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the treatment as well as reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this expertise as well as linked intellectual property from Progenics to CytoDyn, as well as approximately twenty five million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 zillion) plus the very first brand new drug application endorsement ($5 million), and even royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to get a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and many indications, it’s this individual therapies as well as a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

Its opening banner on the site of its (below) shows an active company with diverse interests albeit centered on leronlimab, several illness types, multiple publications in addition to multiple presentations.

Could it all be smoke and mirrors? That’s a question I have been asking myself with the very start of my interest in this business. Judging by way of the multiples of a huge number of diverse responses on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this particular question.

CytoDyn is a traditional battleground, or even some may say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *